《思略特：2025 AI对全球医疗行业的颠覆性影响研究报告：制药与生命科学行业战略路径（英文版）（40页）.pdf》由会员分享，可在线阅读，更多相关《思略特：2025 AI对全球医疗行业的颠覆性影响研究报告：制药与生命科学行业战略路径（英文版）（40页）.pdf（40页珍藏版）》请在三个皮匠报告上搜索。

1、AIs US$868 billion healthcare revolutionStrategic Ways to Play for Pharma and Life Sciences in the Future of HealthContactsGlobalAnthony BruceGlobal Health Industries Leader,Partner,PwC UK+44-7801-916-EuropeDr.Christian KasparPartner,PwC Strategy&Germany+49-170-936-Dr.Thomas SolbachPartner,PwC Strat

2、egy&Germany+49-170-2238-John HaranDirector,PwC Ireland+353-87-960-United StatesSiddhartha BhattacharyaPartner,PwC US+1-484-264-0153siddhartha.bhattacharya AustraliaNicola LynchPartner,PwC Australia+61-425-147-Vivek OdhavDirector,PwC Australia+61-413-707-IsraelPavel SheynkmanDirector,PwC Israel+972-5

3、2-873-JapanKen OmoriPartner,PwC Japan+81-80-7517-IndiaTushar BaksiDirector,PwC India+91-98335-Strategy&|AIs US$868 billion healthcare revolution3Dr.Christian Kaspar is a Partner with Strategy&Germany based in Munich.He leads the Digital and Technology Strategy practice in Europe and advises clients

4、in the pharma and life sciences,MedTech and healthcare industries on data and AI strategies,IT transformation projects as well as technology innovations.Dr.Thomas Solbach is a Partner with Strategy&Germany based in Frankfurt.He leads the Pharma and Life Sciences practice in Europe and specializes in

5、 helping biopharma,diag-nostics,and digital health solution providers to develop differentiated strategies,capabilities,innovations and resilient operating models with a particular focus on precision medicine.Anthony Bruce is a Partner with PwC UK based in London.As PwCs Global Health Industry Leade

6、r,he drives innovation and collaboration in healthcare,pharmaceuticals and life sciences,focusing particularly on delivering improved performance through HR and people-related change programs.Kariem Schlieper is a Director with Strategy&Switzerland.Based in Zurich,he advises clients at the intersect